Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo and Lilly face growing offensive from licensed copies
In weight loss battle, Novo and Lilly face growing offensive from licensed copies
As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented remedies are winning approval from some regulators overseas, posing a threat to the pharma giants' prices and market share.
Lilly’s US Weight-Loss Drug Shortage Ends, Curtailing Copies
Eli Lilly & Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in the US, which means compounding pharmacies must stop making less expensive copycat versions in the coming months.
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
The weight-loss drugs battle has grabbed Wall Street's attention and stoked shares of Eli Lilly and Novo Nordisk. But others are coming.
3d
This Is Huge News for Eli Lilly Investors
Eli Lilly just gave investors several reasons to cheer.
2d
Ozempic MDL Expands to Include New Drugs, but Not New Injuries
"An MDL that encompassed any potential injury relating to use of these exceedingly popular weight loss drugs might quickly ...
2d
on MSN
Novo Nordisk Stock Crashes More Than 20% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar.
Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and ...
1d
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
2d
Ozempic lures people to the doctor, Nestle's GLP-1 'shot,' an FDA Zepbound ruling: Pharma news roundup
Nestle just rolled out a new protein shot drink that it says will help people looking to lose weight manage their hunger and ...
1d
Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...
2d
Novo Nordisk Stock Crashes 22% After Disappointing Obesity Drug Data. Eli Lilly Soars.
Dow, S&P 500, and Nasdaq futures are dropping in premarket trading Friday ahead of the PCE inflation report and as a federal government shutdown looms.
9d
RFK Jr. on Ozempic, Eli Lilly's next test, and Elon Musk gets on the bandwagon: Pharma news roundup
Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...
FiercePharma
2d
FDA reaffirms decision to erase Eli Lilly's tirzepatide from shortage list, halting future flow of knockoffs
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...
NJBIZ
2d
EU reportedly reviewing link between Ozempic, rare eye disease
With U.S. headquarters in Plainsboro, Novo Nordisk told NJBIZ, "NAION is a very rare eye disease, and it is not an adverse ...
1d
on MSN
Novo Nordisk stock price takes a tumble after the Wegovy maker’s next-generation weight-loss drug underwhelms
Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback